Luxury smartwatch maker Withings is set to launch the ScanWatch in North America this November. The smartwatch comes with some impressive innovations and happens to be the first FDA-cleared smartwatch to feature both ECG and blood oxygen level monitoring via some new sensors.
The United States Food and Drug Administration (FDA) is the regulatory body for such health-related features. The new smart wearable device will be able to measure atrial fibrillation and blood oxygen levels, which are very important health and fitness metrics.
The ECG and SpO2 monitoring offer an additional layer of health safety for users. In a press release, Withings stated that the ScanWatch is the first smart wearable to record both ECG and SpO2 measurements, and will help to detect significant departure from the normal readings to trigger further health intervention. The wearable has been clinically validated and can aid in the detection of breathing disturbances indicative of some deeper respiratory issues.
The ScanWatch will be a useful health and fitness companion for its users. It has a degree of water resistance up to 5 atmospheres, a 30-day battery life, and will have a starting price tag of $277 for the smaller model while the bigger watch will cost $299. From November 1, the ScanWatch will be available via the Withings website, Amazon, or Best Buy.
The Withings ScanWatch comes with a design philosophy quite different from some of the popular smart wearables. Rather than touchscreens, the ScanWatch is a combination of dials and digital screens giving a traditional appeal to the tech-powered smartwatch.
RELATED:
- Huawei starts sale of New SERES SF5 Car in its China Flagship Stores
- Huawei is selling some of its flagship phones without a charging adapter in the box
- Huawei adds Headspace app to AppGallery, to offer wellbeing support to its customers
- Huawei launches new AppGallery promotion to support businesses during pandemic
(via)
